Solventum Corporation (SOLV) Stock

Solventum Corporation (SOLV) is a Healthcare stock trading at $88.63 (as of 2026-08-20), with a market capitalization of $15.35B and a trailing P/E of 10.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Solventum Corporation is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions across four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Its offerings range from clinical products and software to purification and filtration technologies, serving healthcare customers and patients.

Understand Solventum Corporation: how it makes money

Solventum develops, manufactures, and commercializes healthcare solutions, selling a portfolio that includes Medsurg wound care and surgical items, Dental Solutions products, Health Information Systems, and Purification and Filtration solutions, with revenue coming from net sales of products plus software and rentals.

Solventum’s profit depends on the revenue mix between net sales of physical healthcare products and net sales of software and rentals.

Business quality (Weak): Good transparency on overall profitability (gross margin and operating margin) and revenue sources (products versus software and rentals), but there is no provided segment revenue breakdown for the four official segments, and there are no listed operational KPIs to track day to day.

Valuation: At 10× earnings, SOLV trades 70% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Diversified solution portfolio across clinical and workflow needs: The company operates through four segments, including Medsurg (for example advanced wound care and sterilization assurance), Dental Solutions, Health Information Systems, and Purification and Filtration.
  • Healthy gross profitability: Latest quarter gross margin is 54.7%, indicating strength at the product and service gross-profit level.

Bear case

  • Thin operating margin: Latest quarter operating margin is 4.0%, which can leave limited room to absorb cost pressures.
  • Profit sensitivity to mix between products and software or rentals: The company reports net sales split between product sales and software and rentals, so changes in that mix can affect overall profitability.
Valuation — source: SEC EDGAR (first-party)
Price$88.63
Market Cap$15.35B
P/E Ratio10.7
EV / EBITDA7.6
Price / Book3.09
Price / Sales1.86
FCF Yield-1.3%
DCF Value (model)$138.40
DCF Upside vs Price56.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$8.32B
Net Margin18.7%
Revenue Growth (YoY)-3.0%
EPS Growth (YoY)-91.1%
FCF Growth (YoY)241.3%
Financial Health — source: SEC EDGAR
Altman Z-Score2.32 (grey)
Valuation vs Sector & Industry
Stock P/E10.7
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector-50.4%
vs Industry-67.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($1.35B)
Institutional Holders Tracked10
Congressional Trades (recent)8
Company
SectorHealthcare
IndustryMedical Equipment
CEOBryan C. Hanson
Employees22,000
CountryUS
IPO Date2024-04-01

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • ResMed Inc. (RMD)
  • Medline Inc. (MDLN)
  • West Pharmaceutical Services, Inc. (WST)
  • Baxter International Inc. (BAX)
  • Penumbra, Inc. (PEN)
  • Globus Medical, Inc. (GMED)
  • Glaukos Corporation (GKOS)
  • Insulet Corporation (PODD)
SOLV earnings history · SOLV institutional & insider holders · SOLV KPIs & operating metrics · SOLV financials · SOLV investor presentations & press releases · SOLV SEC filings · SOLV peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.